IonQ Unveils Its First Quantum Computer in Europe, Online Now at a Record #AQ36
5.12.2024 14:05:00 CET | Business Wire | Press release
IonQ’s quantum computer Forte Enterprise has achieved the record-breaking milestone of #AQ36In partnership with QuantumBasel, IonQ Forte Enterprise will provide European Enterprise Customers, Industries, government entities, and research institutes with local access to IonQ’s most powerful quantum systemsIonQ has opened its First European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the delivery of IonQ Forte Enterprise to its first European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland. Achieved in partnership with QuantumBasel, this major milestone marks the first datacenter-ready quantum computer IonQ has delivered that will operate outside the United States and the first quantum system for commercial use in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205805000/en/

IonQ European Innovation Center - Arlesheim, Switzerland (Photo: Business Wire)
Forte Enterprise is now online servicing compute jobs while performing at a record algorithmic qubit count of #AQ36, which is significantly more powerful than the promised #AQ35. With each additional #AQ, the useful computational space for running quantum algorithms doubles. A system with #AQ36 is capable of considering more than 68 billion different possibilities simultaneously. With this milestone, IonQ once again leads the industry in delivering production-ready systems to customers.
“The successful commissioning of Forte Enterprise in Europe – on schedule and at an even higher performance level than announced previously – demonstrates IonQ’s commitment to driving global quantum adoption through technological leadership and operational excellence,” said Peter Chapman, CEO and President of IonQ. “Achieving #AQ36 is a significant leap forward, opening new possibilities for applications including logistics, finance, pharmaceuticals, chemistry and artificial intelligence.”
“Offering the state-of-the-art Forte Enterprise quantum computing platform to our ecosystem will accelerate the development of quantum applications across a range of fields,” said Damir Bogdan, CEO of QuantumBasel. “By collaborating with IonQ, we’re positioning the uptownBasel campus as a leader in quantum innovation, fostering breakthroughs that address real-world challenges.”
IonQ’s next generation commercial quantum systems such as Forte Enterprise are optimized for data center environments, sporting a rack-mounted form factor, low energy profile, and minimal environmental isolation requirements.
Building on a History of Excellence
Today’s IonQ Forte Enterprise system commissioning represents the culmination of IonQ’s engineering innovation, operational excellence, and enterprise-grade production capabilities.
“This milestone reflects the hard work and ingenuity of teams across IonQ and QuantumBasel,” said Dr. Dave Mehuys, VP of Production Engineering. “We aligned our system build with on-site datacenter construction and IonQ’s manufacturing and production teams leveraged their decades of expertise to bring this groundbreaking system online faster than anticipated.”
Pioneering a New Era of Computing
IonQ’s record-breaking achievement of #AQ36 signals the company’s dedication and success in advancing quantum performance. Forte Enterprise expands the potential for driving groundbreaking research in areas such as quantum chemistry and machine learning.
“IonQ’s ability to deliver Forte Enterprise with #AQ36 reflects our growing capabilities to execute on our mission to drive significant quantum advancements globally,” said Dr. Dean Kassmann, Senior Vice President of Engineering and Technology at IonQ. “Each step we take demonstrates our commitment to bringing quantum computing from the lab to practical, impactful, and commercial uses.”
A Quantum Leap for Europe and Beyond
IonQ’s first European Innovation Center will allow the company to service its European customers out of its QuantumBasel location and to drive research and development of next generation quantum applications in Europe.
As part of its partnership with IonQ, QuantumBasel will offer its ecosystem– including enterprises, research institutes, startups, and universities – direct access to the #AQ36 Forte Enterprise system.
With datacenters now in the Washington, D.C., Seattle, and Basel, Switzerland areas, IonQ has firmly established a global data center footprint, reinforcing its position as a leader in quantum technology.
To learn more about IonQ’s latest innovations, visit www.ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
About QuantumBasel
QuantumBasel is a competence center for quantum computing and AI and drives access to commercial quantum computing to foster innovation. QuantumBasel places particular emphasis on technological neutrality and is Switzerland’s first commercial quantum computing hub, providing access to hardware from IBM, D-Wave and IonQ. QuantumBasel’s team of quantum and data scientists trains and supports companies, conducts projects in quantum computing and AI, and collaborates closely with universities and academic institutions. Through an internationally connected ecosystem, QuantumBasel provides access to advanced know-how and technologies, enabling companies in industrial production, logistics, finance, energy, life sciences, and start-ups to achieve innovations they cannot develop independently. www.quantumbasel.com
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the terms “adoption,” “advancing,” “advancements,” “collaborating,” “commitment,” “demonstrates,” “development,” “groundbreaking” “milestone,” “next generation,” “optimized,” “potential,” “significant leap forward,” “state-of-the-art,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial quantum advantage in the future, the timing of delivering to customers IonQ Forte Enterprise systems, the planned increase to the footprint of the uptownBasel campus in Arlesheim, Switzerland, the company’s ability to establish public-private partnerships, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, access to IonQ’s quantum computers, the ability to test and execute quantum applications on IonQ’s quantum computers, the opportunity to test and optimize novel quantum-enhanced algorithms for computational challenges on IonQ’s quantum computers; the problems that can be solved by IonQ’s quantum computers, the advantages of IonQ's approach to the manufacturing of IonQ’s systems, IonQ’s quantum computing capabilities and plans, and the scalability and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates; the ability of IonQ to protect its intellectual property; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, technical roadmap, and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; or market adoption of quantum computing solutions and IonQ’s products, services and solutions. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205805000/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom